Jeremy Bender Sells 15,459 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 15,459 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the transaction, the chief executive officer owned 204,603 shares in the company, valued at $2,373,394.80. This represents a 7.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Day One Biopharmaceuticals Stock Down 2.7%

Shares of DAWN stock traded down $0.32 during trading hours on Wednesday, hitting $11.56. 1,478,926 shares of the company’s stock were exchanged, compared to its average volume of 2,543,632. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The firm has a market cap of $1.19 billion, a P/E ratio of -7.61 and a beta of -1.26. The firm has a 50 day moving average of $10.28 and a two-hundred day moving average of $8.55.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Piper Sandler boosted their target price on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. TD Cowen assumed coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Finally, Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Day One Biopharmaceuticals by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock valued at $58,552,000 after buying an additional 101,047 shares during the period. Vestal Point Capital LP raised its stake in shares of Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after acquiring an additional 2,525,000 shares in the last quarter. Deerfield Management Company L.P. boosted its holdings in Day One Biopharmaceuticals by 26.4% in the third quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after purchasing an additional 982,282 shares during the period. State Street Corp raised its position in Day One Biopharmaceuticals by 32.4% in the 4th quarter. State Street Corp now owns 4,289,566 shares of the company’s stock valued at $39,979,000 after purchasing an additional 1,049,122 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Day One Biopharmaceuticals by 2.0% in the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock valued at $26,635,000 after purchasing an additional 79,255 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.